Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Study of Safety, Pharmacokinetic and Efficacy of Orally Administered APG-5918 in Patients With Advanced Solid Tumors or Hematologic Malignancies

NCT05415098 is registered in ClinicalTrials.gov with Ascentage Pharma Group Inc. as lead sponsor.

NCT NCT05415098
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05415098 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Study of Safety, Pharmacokinetic and Efficacy of Orally Administered APG-5918 in Patients With Advanced Solid Tumors or Hematologic Malignancies
Lead sponsor
Ascentage Pharma Group Inc.
Phase
Phase 1
Overall status
Unknown status
Start date
September 30, 2022
Completion date
September 30, 2025
Enrollment
90 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

b cell lymphoma, castrate resistant prostate cancer, epithelioid sarcoma, gastric cancer, mesothelioma, nasopharyngeal carcinoma, non hodgkin lymphoma, ovarian clear cell carcinoma, sarcoma